What the Study Found
Biotechnology company EG 427 announced on January 6, 2026 that patients receiving their EG110A gene therapy maintained an 88% reduction in urinary incontinence episodes through 24 weeks of follow-up. This sustained effect, first observed at 12 weeks, represents a potential shift in how neurogenic bladder dysfunction might be treated in the future.
The ongoing Phase 1b/2a clinical trial (ClinicalTrials.gov ID: NCT06596291) is evaluating EG110A in people with neurogenic detrusor overactivity (NDO) caused by spinal cord injury. The study is currently enrolling its second cohort at four leading U.S. medical institutions in California, Michigan, Pennsylvania, and Texas.
Dr. Cornelia Haag-Molkenteller, Chief Medical Officer at EG 427, stated in the company's press release: "Following the very promising initial clinical results at 12 weeks, we are seeing the first patients maintaining a highly clinically relevant reduction in urinary incontinence episodes at 24 weeks, a major milestone in EG110A's clinical development."
Trial Results at 24 Weeks
- 88% reduction in urinary incontinence episodes sustained through 24 weeks
- Good safety profile maintained with no new safety signals
- Lowest dose tested achieved these results—higher doses now being evaluated
- Long-term monitoring continuing to 52 weeks, followed by observational study
Understanding Neurogenic Detrusor Overactivity
Neurogenic detrusor overactivity (NDO) occurs when nerve damage causes the bladder muscle to contract uncontrollably. In spinal cord injury, the nerve pathways between the brain and bladder become disrupted, leading to involuntary bladder contractions that cause urinary incontinence.
The condition affects 70-84% of people living with spinal cord injury—an estimated 300,000 to 400,000 people worldwide. Beyond incontinence, NDO creates risk for kidney damage and urinary tract infections that can lead to death in 5-10% of the SCI population according to EG 427's data.
NDO also affects people with other neurological conditions including multiple sclerosis and Parkinson's disease, bringing the total affected population to at least 2 million patients across major global markets.
NDO by the Numbers
| Measure | Figure |
|---|---|
| SCI patients affected by NDO | 70-84% |
| Estimated SCI population with NDO worldwide | 300,000-400,000 |
| Total NDO patients across conditions | 2+ million globally |
| European economic burden (2023) | €69.1 billion |
| UTI-related mortality risk in SCI | 5-10% |
Source: EG 427 Press Release, January 6, 2026; European Association of Urology
How EG110A Works
Targeting Specific Sensory Neurons
EG110A uses a non-replicating herpes simplex virus type 1 (HSV-1) vector—a virus that has been modified so it cannot reproduce—to deliver therapeutic genetic material. The treatment specifically targets type C sensory neurons, which are responsible for triggering the overactive bladder muscle contractions that cause incontinence.
What makes this approach different from existing treatments is its precision. The therapy silences only the nerve signals causing the bladder muscle overactivity while preserving other bladder control functions. Traditional treatments often affect broader bladder function or require repeated interventions.
Dr. Philippe Chambon, CEO of EG 427, explained: "What is truly remarkable, is that by targeting a very small number of sensory neurons, we are able to achieve such a dramatic improvement for the patients."
Treatment Administration
Participants in the study receive a single treatment course consisting of multiple intradetrusor injections—injections directly into the bladder muscle wall. The study enrolls adult participants with NDO following SCI who have persistent urinary incontinence despite standard care therapy and who perform clean intermittent catheterization regularly.
The HERMES Platform Technology
EG 427's proprietary HERMES platform delivers what the company calls "pinpoint neurotherapeutics." The technology enables:
Focal transduction in specific regions of the nervous system
Selective expression of therapeutic genes in targeted neuron subsets
Large payload capacity allowing delivery of complex genetic material
Potential for repeated dosing if needed in the future
Current Treatment Options for NDO
People with NDO currently manage the condition through several approaches, each with limitations:
Anticholinergic medications can reduce bladder contractions but often cause side effects including dry mouth, constipation, and cognitive effects, particularly in older adults. Many people discontinue these medications due to side effect burden.
Botulinum toxin injections (Botox) into the bladder muscle can provide relief for several months, but effects wear off and require repeated treatments every 6-9 months. Each injection session carries procedure-related risks.
Clean intermittent catheterization helps empty the bladder but does not address the underlying overactivity that causes incontinence between catheterizations.
A one-time treatment that provides lasting incontinence reduction—which EG110A may potentially offer—would address a significant unmet need in bladder management for people with SCI.
Treatment Approaches Compared
| Treatment | Frequency | Considerations |
|---|---|---|
| Anticholinergic Medications | Daily oral dosing | Side effects limit long-term use for many patients |
| Botulinum Toxin Injections | Every 6-9 months | Effects temporary; requires repeated procedures |
| Intermittent Catheterization | Multiple times daily | Does not prevent incontinence between catheterizations |
| EG110A Gene Therapy (investigational) | Single treatment course | In early clinical trials; long-term effects under study |
What This Means for the SCI Community
Urinary incontinence remains one of the most challenging secondary conditions affecting people with spinal cord injury. Beyond the physical management demands, incontinence affects employment, social participation, relationships, and mental health.
Dr. Haag-Molkenteller noted: "For patients, this drop in incontinence episodes combined with a long-term effect could dramatically improve quality of life."
The economic burden of managing incontinence is also substantial. The European Association of Urology estimated that incontinence caused by NDO and related conditions represents an economic burden exceeding €69.1 billion in Europe during 2023.
Living with NDO After SCI
People with spinal cord injury consistently rank bladder function among their highest priorities for improving quality of life. Neurogenic bladder dysfunction can affect:
The Clinical Trial in Detail
The Phase 1b/2a study is an open-label, dose-escalation trial designed to evaluate safety and preliminary efficacy of EG110A. "Open-label" means both researchers and participants know they are receiving the treatment (there is no placebo group). "Dose-escalation" means the study tests progressively higher doses in different groups of participants.
Study Design
The first cohort received the lowest dose being tested. Even at this starting dose, participants experienced the 88% reduction in incontinence episodes reported in the press release. The second cohort is now receiving a higher dose to evaluate whether increased dosing provides additional benefit.
Participants will be followed for up to 52 weeks during the main study period, then invited to enroll in a long-term observational study to track how long the treatment effects persist.
About the Clinical Trial
Who May Be Eligible
The study enrolls adults with NDO following spinal cord injury who meet these general criteria:
- Have neurogenic detrusor overactivity caused by spinal cord injury
- Experience persistent urinary incontinence despite standard care therapy
- Perform clean intermittent catheterization on a regular basis
Specific eligibility criteria are determined by the research team. Those interested in learning more should contact the study sites directly or visit ClinicalTrials.gov.
About EG 427
EG 427 is a biotechnology company headquartered in Paris, France, focused on developing what they describe as "pinpoint DNA medicines" for chronic neurological diseases. The company is developing the first non-replicating HSV-1 vector therapy targeting sensory neuron-based diseases.
The EG110A program is being developed not only for neurogenic bladder related to SCI, but also for overactive bladder (OAB) affecting the broader population. The technology platform has applications across diseases of the peripheral and central nervous system.
This research was supported in part by the U.S. Department of Defense through the Spinal Cord Injury Research Program under Award No. HT9425-25-1-0505, providing $3,165,836 in funding.
Learn More About This Research
Visit EG 427's website for official press releases and company information, or search ClinicalTrials.gov for detailed study information.
Looking Forward
While these early results are promising, EG110A remains in early-stage clinical development. The company will continue following current participants through 52 weeks and is evaluating higher doses in the second cohort. Larger studies will be needed to confirm efficacy and safety across a broader patient population.
Gene therapy for neurogenic bladder represents one of several research approaches aimed at improving bladder function after spinal cord injury. Other areas of active investigation include neuromodulation, stem cell therapies, and improved botulinum toxin formulations.
NASCIC will continue to monitor developments in this clinical program and provide updates as new data become available.
Medical Information Disclaimer
This article is for educational purposes only and is based on the company press release dated January 6, 2026. This content does not constitute medical advice. Consult with your healthcare provider before making any decisions about your treatment. EG110A is an investigational therapy that has not been approved by the FDA or other regulatory agencies.
Source
EG 427 Press Release: "EG 427's Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint." January 6, 2026. Paris, France.
Additional information from the European Association of Urology socio-economic report on incontinence (2023).